02.21.2017, FIT Group JSC (FIT code) has announced the registration of buying 3 million shares of Cuu Long Pharmaceutical JSC. Subscription period from of the transaction is expected from 24/02/2017 to 03/23/2017.
With this plan, after completing of the purchase, FIT ownership will increase to 69.95 % charter capital instead of 64.62% as current charter capital.
2017, DCL planned to achieved 914 billion in net revenue, an increase of nearly 24%; profit after tax of 96 billion, respectively up to 24% and 7% compared with the number performed in 2016 with 738 billion in net revenue, 90 billion profit after tax.
2016 is the 3nd consecutive years, DCL growth in business results, which in 2015, profit after tax increased to more than 91% compared to 2014; 2016, profit after tax increased by 50% compared to 2015.
2016, DCL impress not only on business results, but also successful implementation the acquisitions of Euvipharm, pharmaceutical members of Valeant – Canada.
